Fig. 7

B4GALT5 function loss experiment in vitro. (A) The expression of B4GALT5 in OC patient(Normal tissue n = 12, ovarian cancer n = 57). (B) The knockdown efficiency of B4GALT5 was assessed in both A2780 and SKOV3 cells using the western blotting technique. (C) The cell viability of A2780 and SKOV3 cells was evaluated utilizing the CCK-8 assay. (D-E) Flow cytometry and AO/EB staining were utilized to assess cellular apoptosis in A2780 and SKOV3 cells. (F) Trans well assay was used to compare B4GALT5 knockdown cells with control-si cells, and the results are presented as mean ± standard error of the mean. (*P < 0.05 compared to control-si group)